Postprandial plasma lipid levels are influenced by the interaction of functional polymorphisms in the microsome triglyceride transfer protein and β3 adrenergic receptor genes

Medical Science Monitor

Volumn 13, Issue 5, 2007, Pages

  Ueno, Takahiro ^a,b   Takahashi, Yumiko ^a   Matsumoto, Taro ^a   Tsunemi, Akiko ^a   Watanabe, Hideyuki ^a   Tahira, Kazunobu ^a   Fukuda, Noboru ^a   Soma, Masayoshi ^a   Matsumoto, Koichi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE   (Japan)

Author keywords

3 adrenergic receptor; Glucose intolerance; Hypertriglyceridemia; Microsome triglyceride transfer protein; Postprandial hyperlipidemia

Indexed keywords

ARGININE; BETA 3 ADRENERGIC RECEPTOR; CARRIER PROTEIN; GLUCOSE; IMMUNOREACTIVE INSULIN; LIPID; MICROSOME TRIGLYCERIDE TRANSFER PROTEIN; TRIACYLGLYCEROL; TRYPTOPHAN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; GENE INTERACTION; GENOTYPE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; LIPID BLOOD LEVEL; LIPID METABOLISM; MICROSOME; NORMAL HUMAN; ORAL GLUCOSE TOLERANCE TEST; POSTPRANDIAL STATE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANIMALS; CARRIER PROTEINS; GENOTYPE; GLUCOSE; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC; POSTPRANDIAL PERIOD; RATS; RECEPTORS, ADRENERGIC, BETA-3; TRIGLYCERIDES;

EID: 34248198289     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Goldstein JL, Schrott HG, Hazzard WR et al: Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest, 1973; 52: 1544-68
2. Brunzell JD, Albers JJ, Chait A et al: Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res, 1983; 24: 147-55
3. Hidvegi T, Hetyesi K, Biro L et al: Screening for metabolic syndrome in hypertensive and/or obese subjects registered in primary health care in Hungary. Med Sci Monit, 2003; 9(7): CR328-34
4. Kwiterovich PO Jr, Coresh J, Bachorik PS: Prevalence of hyperapobetalipoproteinemia and other lipoprotein phenotypes in men (aged < or =50 years) and women (< or =60 years) with coronary artery disease. Am J Cardiol, 1993; 71: 631-39
5. Cullen P, Farren B, Scott J et al: Complex segregation analysis provides evidence for a major gene acting on serum triglyceride levels in 55 British families with familial combined hyperlipidemia. Arterioscler Thromb, 1994; 14: 1233-49
6. Jarvik GP, Brunzell JD, Austin MA et al: Genetic predictors of FCHL in four large pedigrees. Influence of ApoB level major locus predicted genotype and LDL subclass phenotype. Arterioscler Thromb, 1994; 14: 1687-94
7. Juo SH, Bredie SJ, Kiemeney LA et al: A common genetic mechanism determines plasma apolipoprotein B levels and dense LDL subfraction distribution in familial combined hyperlipidemia. Am J Hum Genet, 1998; 63: 586-94
8. Uiterwaal CS, Grobbee DE, Witteman JC et al: Postprandial triglyceride response in young adult men and familial risk for coronary atherosclerosis. Ann Intern Med, 1994; 121: 576-83
9. Babirak SP, Brown BG, Brunzell JD: Familial combined hyperlipidemia and abnormal lipoprotein lipase. Arterioscler Thromb, 1992; 12: 1176-83
10. Yang WS, Nevin DN, Iwasaki L et al: Regulatory mutations in the human lipoprotein lipase gene in patients with familial combined hyperlipidemia and coronary artery disease. J Lipid Res, 1996; 37: 2627-37
11. Pihlajamaki J, Karjalainen L, Karhapaa P et al: G-250A substitution in promoter of hepatic lipase gene is associated with dyslipidemia and insulin resistance in healthy control subjects and in members of families with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol, 2000; 20: 1789-95
12. Pihlajamaki J, Rissanen J, Heikkinen S et al: Codon 54 polymorphism of the human intestinal fatty acid binding protein 2 gene is associated with dyslipidemias but not with insulin resistance in patients with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol, 1997; 17: 1039-44
13. Bjorn L, Leren TP, Ose L et al: A functional polymorphism in the promoter region of the microsomal triglyceride transfer protein (MTP - 493G/T) influences lipoprotein phenotype in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol, 2000; 20: 1784-88
14. Meijssen S, Cabezas MC, Twickler TB et al: In vivo evidence of defective postprandial and postabsorptive free fatty acid metabolism in familial combined hyperlipidemia. J Lipid Res, 2000; 41: 1096-102
15. Sniderman AD, Cianflone K, Arner P et al: The adipocyte, fatty acid trapping, and atherogenesis. Arterioscler Thromb Vasc Biol, 1998; 18: 147-51
16. Ueno T, Tremblay J, Kunes J et al: Gender-specific genetic determinants of blood pressure and organ weight: pharmacogenetic approach. Physiological Research, 2003; 52: 689-700
17. Karpe F, Lundahl B, Ehrenborg E et al: A common functional polymorphism in the promoter region of the microsomal triglyceride transfer protein gene influences plasma LDL levels. Arterioscler Thromb Vasc Biol, 1998; 18: 756-61
18. Krief S, Lonnqvist F, Raimbault S et al: Tissue distribution of beta 3-adrenergic receptor mRNA in man. J Clin Invest, 1993; 91: 344-49
19. Emorine L, Blin N, Strosberg AD: The human beta 3-adrenoceptor: the search for a physiological function. Trends Pharmacol Sci, 1994; 15: 3-7
20. Yoshida T, Sakane N, Umekawa T et al: Mutation of beta 3-adrenergic-receptor gene and response to treatment of obesity. Lancet, 1995; 346: 1433-34
21. Widen E, Lehto M, Kanninen T et al: Association of a polymorphism in the beta 3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med, 1995; 333: 348-51
22. Harsch IA, Hahn EG, Konturek PC: Insulin resistance and other metabolic aspects of the obstructive sleep apnea syndrome. Med Sci Monit, 2005; 11(3): RA70-75
23. Okumura K, Matsui H, Ogawa Y et al: The polymorphism of the beta3-adrenergic receptor gene is associated with reduced low-density lipoprotein particle size. Metabolism, 2003; 52: 356-61
24. Grundy SM: United States Cholesterol Guidelines 2001: expanded scope of intensive low-density lipoprotein-lowering therapy. Am J Cardiol, 2001; 88: 23J-27J
25. Aitman TJ, Glazier AM, Wallace CA et al: Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet, 1999; 21: 76-83
26. de Roos B, Caslake MJ, Ardern HA et al: Insulin resistance in the St. Thomas' mixed hyperlipidaemic (SMHL) rabbit, a model for familial combined hyperlipidaemia. Atherosclerosis, 2001; 156: 249-54
27. Kloting I, Kovacs P, van den Brandt J: Sex-specific and sex-independent quantitative trait loci for facets of the metabolic syndrome in WOKW rats. Biochem Biophys Res Commun, 2001; 284: 150-56
28. Castellani LW, Weinreb A, Bodnar J et al: Mapping a gene for combined hyperlipidaemia in a mutant mouse strain. Nat Genet, 18: 374-77
29. St-Pierre J, Lemieux I, Miller-Felix I et al: Visceral obesity and hyperinsulinemia modulate the impact of the microsomal triglyceride transfer protein -493G/T polymorphism on plasma lipoprotein levels in men. Atherosclerosis, 2002; 160: 317-24
30. Berthier MT, Houde A, Paradis AM et al: Molecular screening of the microsomal triglyceride transfer protein: association between polymorphisms and both abdominal obesity and plasma apolipoprotein B concentration. J Hum Genet, 2004; 49: 684-90
31. Ukkola O, Rankinen T, Weisnagel SJ et al: Interactions among the alpha2-, beta2-, and beta3-adrenergic receptor genes and obesity-related phenotypes in the Quebec Family Study. Metabolism, 2000; 49: 1063-70
32. Pihlajamaki J, Rissanen J, Valve R et al: Different regulation of free fatty acid levels and glucose oxidation by the Trp64Arg polymorphism of the beta3-adrenergic receptor gene and the promoter variant (A-3826G) of the uncoupling protein 1 gene in familial combined hyperlipidemia. Metabolism, 1998; 47: 1397-402